

4557-11484

# **Investigations on the mechanism of action of antiinflammatory glucan sulfates**

**Dissertation**

**zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.)  
der naturwissenschaftlichen Fakultät IV  
– Chemie und Pharmazie –  
der Universität Regensburg**

**vorgelegt von**

**Maria Laffranchini  
aus Monfalcone (Italien)**

**2004**

4557-1484

# **Investigations on the mechanism of action of antiinflammatory glucan sulfates**



**Dissertation**

**zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.)**

**der naturwissenschaftlichen Fakultät IV**

**– Chemie und Pharmazie –**

**der Universität Regensburg**

**vorgelegt von**

**Maria Laffranchini**

**aus Monfalcone (Italien)**

**2004**

# **Investigations on the mechanism of action of antiinflammatory glucan sulfates**



**Dissertation**

**zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.)  
der naturwissenschaftlichen Fakultät IV  
– Chemie und Pharmazie –  
der Universität Regensburg**

vorgelegt von  
**Maria Laffranchini**  
aus Monfalcone (Italien)  
2004

---

<b>A. Introduction.....</b>	<b>1</b>
<b>1. The immune system .....</b>	<b>1</b>
<b>2. Cellular non specific immune system.....</b>	<b>2</b>
2.1. Leucocytes .....	2
2.2. Polymorphnuclear granulocytes (PMN) .....	2
2.3. Monocytes.....	3
<b>3. Leucocyte migration .....</b>	<b>3</b>
3.1. Types of cell movement.....	3
3.2. Chemoattractants .....	4
3.3. Cell adhesion .....	5
<b>4. Cytokines .....</b>	<b>6</b>
4.1. Interleukin-1 (IL-1).....	7
4.2. Tumour necrosis-factor alpha (TNF- $\alpha$ ) .....	7
4.3. Interleukin- 6 (IL-6).....	8
4.4. The chemokine superfamily .....	8
4.4.1. Interleukin-8 (IL-8).....	9
4.5. Interleukin 10 (IL-10) .....	9
<b>5. Complement system.....</b>	<b>10</b>
5.1. Composition of the complement system.....	10
5.1.1. The classical pathway of complement activation .....	10
5.1.2. The alternative pathway of complement activation.....	11
5.1.3. The membrane attack complex (MAC) .....	12
5.1.4. Atypical complement activation .....	12
5.2. Regulators of complement activation (RCA) .....	13
5.3. Diseases related with deficiency of the complement regulation .....	14
<b>6. Immune system and diseases .....</b>	<b>15</b>
<b>7. Actual therapies of inflammatory disorders .....</b>	<b>15</b>
7.1. Nonsteroidal anti-inflammatory drugs (NSAIDS).....	17
7.2. Glucocorticoids.....	17
7.3. Other anti-inflammatory compounds.....	18
7.4. Sulfated polysaccharides as potential antiinflammatory drugs .....	19
7.4.1. Effects of heparin.....	19
7.4.2. Sulfated polysaccharides as alternative of Heparin .....	20
<b>B. Aim of the study .....</b>	<b>21</b>

---

1. Investigated compounds .....	21
2. Choice of the physiological tests .....	21
3. Physiological tests .....	22
<b>C. Preparation and characterisation of semisynthetic sulfated polysaccharides.....</b>	<b>23</b>
1. Choice of the starting compounds .....	23
1.1. Curdlan.....	23
1.2. Laminarin.....	24
1.3. Pullulan.....	24
2. Preparation of semisynthetic sulfated polysaccharides.....	25
2.1. Sulfation of the compounds.....	25
2.2. Fractionation of sulfated polysaccharides.....	25
<b>D. Physiological Testing.....</b>	<b>30</b>
1. Complement activation.....	30
1.1. Pullulan sulfates (PulS) as complement activation inhibitors .....	30
1.1.1. Influence of pullulan sulfates on the classical complement activation.....	30
1.1.2. Influence of pullulan sulfates on the alternative complement activation .....	35
1.2. Curdlan sulfates (CurS) as complement activation inhibitors .....	36
1.2.1. Influence of curdlan sulfates on the classical complement activation.....	36
1.2.2. Influence of curdlan sulfates on the alternative complement activation .....	38
1.3. DS influence on the activity of pullulan sulfates .....	38
1.4. Comparison between PulS and CurS anticomplementary activity .....	39
1.5. Appendix.....	41
1.5.1. Structural parameters and IC <sub>50</sub> values of PulS fractions.....	41
1.5.2. Structural parameters and IC <sub>50</sub> values of CurS fractions.....	42
2. Leukocyte chemotaxis.....	44
2.1. <i>In-vitro</i> investigations of leukocyte chemotaxis .....	44
2.1.1. The Boyden-chamber.....	44
2.2. Cells for chemotaxis experiments.....	46
2.2.1. PMN and monocyte isolations.....	46
2.2.2. Investigations on human monocytic cell line MonoMac-6 chemotaxis .....	47
2.3. Chemotactic agents.....	47

---

2.3.1. Zymosan-activated-serum, complement fragment C5a and interleukin-8 for PMN-chemotaxis .....	47
2.3.2. MCP-1 and ZAS for monocyte chemotaxis.....	49
2.4. Choice of the membrane.....	50
2.5. Influence of glucan sulfates on chemotaxis.....	51
2.5.1. Effects of PS3 and UFH on PMN chemotaxis.....	51
2.5.2. Structure-activity relationships.....	53
2.5.2.1. Dependency of PMN chemotaxis inhibitory activity on the DS .....	53
2.5.2.2. Influence of the molecular weight on PMN chemotaxis .....	55
2.5.2.3. Dependency of the PMN chemotaxis inhibitory activity on the basic structure .....	57
2.5.3. Effect of PS3 and UFH on monocyte chemotaxis .....	58
2.5.4. Structure-activity relationships.....	59
2.5.4.1. Influence of the degree of sulfation.....	59
2.5.4.2. Influence of the molecular weight.....	60
2.5.4.3. Influence of the basic structure.....	61
2.5.5. Comparison between PMN and monocyte chemotaxis .....	61
2.5.6. Investigations on the mode of action.....	63
2.5.6.1. PS3-cells interactions.....	63
2.5.6.2. PS3-chemoattractant interactions .....	64
2.5.6.3. Influence of PS3 on the chemokinesis.....	65
2.6. Summary and discussion.....	67
<b>3. Investigation of cytokine release.....</b>	<b>68</b>
3.1. Evaluation of parameters influencing the cytokine release .....	68
3.1.1. Time-dependent cytokine release by monocytes.....	68
3.1.2. Induction of cytokine release by U937.....	71
3.1.3. Induction of cytokine release by MonoMac-6.....	73
3.2. Influence of glucan sulfates on the cytokines release.....	74
3.2.1. Cytokine release by LPS-activated monocytes und MonoMac-6.....	74
3.2.2. Cytokine release by LPS-activated monocytes cultivated in the presence of 2% serum.....	78
3.2.3. Spontaneous release of cytokines by non-stimulated monocytes.....	83
3.3. Summary.....	84
<b>E. Summary .....</b>	<b>85</b>

---

<b>1. Antiinflammatory effects of glucan sulfates .....</b>	<b>85</b>
<b>2. Preparation of glucan sulfates .....</b>	<b>85</b>
<b>3. Influence on the complement activation .....</b>	<b>85</b>
<b>4. Influence on the leucocyte chemotaxis .....</b>	<b>85</b>
<b>5. Influence on the cytokine release.....</b>	<b>86</b>
<b>F. Materials and methods .....</b>	<b>87</b>
<b>1. General information .....</b>	<b>87</b>
1.1. Laboratory equipment.....	87
1.2. Laboratory materials .....	88
<b>2. Test compounds.....</b>	<b>88</b>
2.1. Commercially available sulfated polysaccharides .....	88
2.2. Semisynthetic glucan sulfates .....	89
2.3. Synthesis of PulS and CurS .....	89
<b>3. Fractionation of PulS and CurS .....</b>	<b>90</b>
<b>4. Analytic methods.....</b>	<b>91</b>
4.1. Determination of the DS and MW .....	91
<b>5. Complement modulation assay (CMA).....</b>	<b>91</b>
5.1. Classic complement activation investigation (CCMA) .....	92
5.2. Alternative complement activation investigation (ACMA).....	92
<b>6. Leucocyte chemotaxis .....</b>	<b>93</b>
6.1. Leucocyte isolation .....	93
6.2. MonoMac-6 culture .....	95
6.3. Chemotaxis assay .....	96
<b>7. Cytokine release assay .....</b>	<b>98</b>
7.1. Cells .....	99
7.2. Cytokine measurement .....	100
7.3. MTT assay .....	100
<b>8. Abbreviations .....</b>	<b>102</b>
<b>G. Bibliografy .....</b>	<b>103</b>